Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels

Diabetes Care

Volumn 37, Issue 11, 2014, Pages 3054-3060

  El Youssef, Joseph ^a   Castle, Jessica R ^a   Bakhtiani, Parkash A ^a   Haidar, Ahmad ^b   Branigan, Deborah L ^c   Breen, Matthew ^c   Ward, W Kenneth ^a,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c Legacy Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; RECOMBINANT GLUCAGON; RECOMBINANT HUMAN INSULIN; GLUCAGON; GLUCOSE BLOOD LEVEL; INSULIN;

ADULT; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFUSION RATE; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; MALE; NAUSEA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VOMITING; ARTIFICIAL PANCREAS; BLOOD; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE CLAMP TECHNIQUE; METABOLISM; MIDDLE AGED;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCAGON; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIA; INSULIN; MALE; MIDDLE AGED; PANCREAS, ARTIFICIAL;

EID: 84910135619     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0803     Document Type: Article

References (44)

1. Sokal JE. Glucagon dan essential hormone. Am J Med 1966;41:331-341
2. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014;383:69-82
3. Langin D. Diabetes, insulin secretion, and the pancreatic beta-cell mitochondrion. N Engl J Med 2001;345:1772-1774
4. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 2012;122:4-12
5. Farhy LS, McCall AL. Models of glucagon secretion, their application to the analysis of the defects in glucagon counterregulation and potential extension to approximate glucagon action. J Diabetes Sci Tech 2010;4:1345-1356
6. Thorel F, Damond N, Chera S, et al. Normal glucagon signaling and β-cell function after near-total α-cell ablation in adult mice. Diabetes 2011;60:2872-2882
7. Cryer PE. Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 2012;153:1039-1048
8. Kitabchi AE, Gosmanov AR. Safety of rapid-acting insulin analogs versus regular human insulin. Am J Med Sci 2012;344:136-141
9. Lorenzi M, Bohannon N, Tsalikian E, Karam JH. Duration of type I diabetes affects glucagon and glucose responses to insulin-induced hypoglycemia. West J Med 1984;141:467-471
10. Albisser AM, Leibel BS, Ewart TG, et al. Clinical control of diabetes by the artificial pancreas. Diabetes 1974;23:397-404
11. Clemens AH, Chang PH, Myers RW. The development of Biostator, a Glucose Controlled Insulin Infusion System (GCIIS). Horm Metab Res 1977;(Suppl. 7):23-33
12. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008;31:934-939
13. Hovorka R, Kumareswaran K, Harris J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011;342:d1855.
14. Bruttomesso D, Farret A, Costa S, et al. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: preliminary studies in Padova and Montpellier. J Diabetes Sci Tech 2009;3:1014-1021
15. Atlas E, Nimri R, Miller S, Grunberg EA, Phillip M. MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes. Diabetes Care 2010;33:1072-1076
16. Renard E, Place J, Cantwell M, Chevassus H, Palerm CC. Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas. Diabetes Care 2010;33:121-127
17. Sherr JL, Palau Collazo M, Cengiz E, et al. Safety of nighttime 2-hour suspension of basal insulin in pump-treated type 1 diabetes even in the absence of low glucose. Diabetes Care 2014;37:773-779
18. Toffolo G, Bergman RN, Finegood DT, Bowden CR, Cobelli C. Quantitative estimation of beta cell sensitivity to glucose in the intact organism: a minimal model of insulin kinetics in the dog. Diabetes 1980;29:979-990
19. Hovorka R, Canonico V, Chassin LJ, et al. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas 2004;25:905-920
20. Cobelli C, Man CD, Sparacino G, Magni L, De Nicolao G, Kovatchev BP. Diabetes:models, signals, and control. IEEE Rev Biomed Eng 2009;2:54-96
21. Cobelli C, Renard E, Kovatchev B. Artificial pancreas: past, present, future. Diabetes 2011;60:2672-2682
22. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 2011;7:385-395
23. Castle JR, Engle JM, El Youssef J, et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010;33:1282-1287
24. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010;2:27ra27
25. Haidar A, Legault L, Dallaire M, et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ 2013;185:297-305
26. van Bon AC, Luijf YM, Koebrugge R, Koops R, Hoekstra JB, DeVries JH. Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. Diabetes Technol Ther 2014;16:131-136
27. Castle JR, Engle JM, El Youssef J, Massoud RG, Ward WK. Factors influencing the effectiveness of glucagon for preventing hypoglycemia. J Diabetes Sci Tech 2010;4:1305-1310
28. El Youssef J, Castle JR, Branigan DL, et al. A controlled study of the effectiveness of an adaptive closed-loop algorithm to minimize corticosteroid-induced stress hyperglycemia in type 1 diabetes. J Diabetes Sci Tech 2011;5:1312-1326
29. Ward WK, Castle JR, El Youssef J. Safe glycemic management during closed-loop treatment of type 1 diabetes: the role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia. J Diabetes Sci Tech 2011;5:1373-1380
30. Cherrington AD. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 1999;48:1198-1214
31. Marliss EB, Aoki TT, Unger RH, Soeldner JS, Cahill GF Jr. Glucagon levels and metabolic effects in fasting man. J Clin Invest 1970;49:2256-2270
32. Lv D, Breton MD, Farhy LS. Pharmacokinetics modeling of exogenous glucagon in type 1 diabetes mellitus patients. Diabetes Technol Ther 2013;15:935-941
33. Haidar A, Duval C, Legault L, Rabasa-Lhoret R. Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. J Diabetes Sci Tech 2013;7:1507-1512
34. Magni F, Monti L, Brambilla P, Poma R, Pozza G, Galli Kienle M. Determination of plasma [6,6-2H2]glucose enrichment by a simple and accurate gas chromatographic-mass spectrometric method. J Chromatogr A 1992;573:127-131
35. Bequette BW. Glucose clamp algorithms and insulin time-action profiles. J Diabetes Sci Tech 2009;3:1005-1013
36. Haidar A, Potocka E, Boulet B, Umpleby AM, Hovorka R. Estimating postprandial glucose fl uxes using hierarchical Bayes modelling. Comput Methods Programs Biomed 2012;108:102-112
37. Haidar A, Elleri D, Allen JM, et al. Validity of triple- and dual-tracer techniques to estimate glucose appearance. Am J Physiol Endocrinol Metab 2012;302:E1493-E1501
38. Lunn D, Thomas A, Best N, Spiegelhalter D. WinBUGS - A Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325-337
39. Altszuler N. Remembrance: tracing the glucose tracer dilution technique for measuring glucose turnover. Endocrinology 1992;130:3109-3112
40. Ramnanan CJ, Edgerton DS, Kraft G, Cherrington AD. Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab 2011;13(Suppl. 1):118-125
41. Russell SJ, El-Khatib FH, Nathan DM, Damiano ER. Efficacy determinants of subcutaneous microdose glucagon during closed-loop control. J Diabetes Sci Tech 2010;4:1288-1304
42. HartleyM, Thomsett MJ, Cotterill AM. Minidose glucagon rescue for mild hypoglycaemia in children with type 1 diabetes: the Brisbane experience. J Paediatr Child Health 2006;42:108-111
43. Hasan KS, Kabbani M. Mini-dose glucagon is effective at diabetes camp. J Pediatr 2004;144:834
44. Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care 2001;24:643-645